BODENSTEDT MATTHIAS (Chief Financial Officer) sold 6.9% of their position (87.80K shares) of MOONLAKE IMMUNOTHERAPEUTICS on the open market
Open‑market sale worth $1.66M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 4/10/2026ACC: 0001213900-26-042629
Officer· Chief Financial Officer
Since Apr 2022
-87.80K
Net shares
Net seller
$1.66M
Total sold
2
Open market trades
0B · 2S
2
Total transactions
87.80K disposed
Non-Derivative Transactions2
Class A ordinary shares, par value $0.0001 per share
Direct
Shares
−85.87K
Price / share
$18.94
Trade value
$1.63M
% of position
6.7%
4/9/2026
1.28M→1.19M
Class A ordinary shares, par value $0.0001 per share
Direct
Shares
−1.93K
Price / share
$19.51
Trade value
$37.56K
% of position
0.2%
4/10/2026
1.19M→1.19M
Total
Net shares
−87.80K
Net value
-$1.66M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per share Direct | 4/9/2026 | S · Sale | −85.87K | $18.94 | $1.63M | 6.7% | 1.28M | 1.19M |
| Class A ordinary shares, par value $0.0001 per share Direct | 4/10/2026 | S · Sale | −1.93K | $19.51 | $37.56K | 0.2% | 1.19M | 1.19M |
| Total | −87.80K | -$1.66M | ||||||
Derivative Transactions0
No derivative transactions reported